December 9 Biotech Update

The market is pretty crappy to start this morning but let us see if the trend reverses. We have had a lot gap higher opens and then weakness the rest of the day, so perhaps this is a gap down and then strengthen sort of day. I do not think that is going to be […]

December 8 Biotech Update

It has been a busy couple of days as expected and more news than can be adequately covered in one day, so today I will touch on what seems most interesting and/or near term actionable. Even then I will necessarily be leaving some important topics for later in the week so feel free to contact […]

December 5 Biotech Update

Another day and another morning with an opening spike in large cap biotechs that was immediately sold. This is a disturbing pattern and one that needs to break if the sector is going to continue to move higher. Until we can get follow through on these opening moves, we are going to at best treat […]

Catalyst Watch – Vol. 2, Edition 34 (12/5/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]

December 4 Biotech Update

A blah start to the trading day. There are not a particularly large numbers of movers and the market seems for the most part to be drifting. As such, it is difficult to discern any real trend outside of chop. So it seems like the market and sector are searching for a direction. I would […]

December 3 Biotech Update

It is a basically neutral day in the market but the sector seems a little weak but this is off of a good day yesterday. One problem to keep an eye on is that many of the stocks I follow start very strong but weaken throughout the day. I would certainly prefer to stop seeing […]

Quick Note on GWPH

GWPH has been on one huge rollercoaster. After climbing back from $61 in mid-October to $80 in late November, it has given up 15% in just the last 3 trading days, falling back to $68 as the rest of biotech surges following their morning Q3 conference call. Perhaps investors had been expecting more detailed data […]

December 1 Bitoech Update

Markets are weak and the biotech sector is moving with it and it appears that small cap and momentum plays are being most affected (large caps seem to be holding up fairly well). The market probably needs to consolidate its recent move as do a lot of biotechs but the wild cards this month are […]

November 26 Biotech Update

The trading is winding down as we approach Thanksgiving and I suspect today is going to be slow and get slower. The market will be open again on Friday but will likely be even slower as many will likely take the half trading day off. I suspect this also means that news flow will also […]

Quick Survery

We are constantly looking for was to improve Chimera and ensure that everyone is getting value for their money. As part of this process, we are looking for feedback from you all. Please take the time to fill out this quick survey, so we can learn where we need to improve and what you find […]

November 24 Biotech Update

A decent start to the week but volume is going to be low all week and I suspect that will increase the chop. So I would not read anything into the broader sector outside of this week having a slight positive bias. That being said, we do have to respect any move that is done […]

What to Look For at ASH 2014

  The year is nearly over, though it feels like scientific conferences never end. December 6th marks the last big Cancer meeting of the year- then we turn the page to 2015. We’ve put together a list of over a dozen companies presenting at ASH, along with data we believe investors will be looking for: AGIO […]

November 21 Biotech Update

A great open for the market but then it immediately proceeded to lay an egg. It is still early and the key is going to be how it responds to the selling. The only worrying sign is that the downdraft really seemed to hit biotechs and these have been a leading indicator of larger market […]

Catalyst Watch – Vol. 2, Edition 33 (11/20/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]

November 20 Biotech Update

Market starts a little weak this morning and generally is taking the sector with it. That being said it is not a rout by any means, so it seems like there sector is looking to find its footing before the next move. Luckily we have some news to talk about. 1. EPZM reported very positive […]

November 19 Biotech Update

A weak start to the morning both in the broader market and biotech sector and this is on the back of a good day yesterday. It just reinforces the view that the market seems to have almost no memory from day to day. Luckily we have some interesting data to talk about. 1. The talk […]

November 17 Biotech Update

This morning was just a little bit busy. The market was neutral, which gives us a nice clean way to see how the biotechs are reacting to news. In general, it appears that good news is still moving stocks higher, although some of the moves were more muted than you would expect. In any case, […]

November 14 Biotech Update

The markets are fine this morning but biotech is weak and seems to be led lower by GILD and other large caps. As long as GILD is weak it is going to be difficult for the sector to lead and this could eventually spill over into the broader markets. We have quickly moved from extremes […]